Related Experiment Video
Updated: Jul 10, 2026
08:33
Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time
Published on: March 11, 2021
K(ATP) channel pharmacogenomics: from bench to bedside.
S Sattiraju1, S Reyes, G C Kane
1Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Clinical Pharmacology and Therapeutics
|October 25, 2007
Summary
Genetic variations significantly influence how individuals respond to drugs and experience toxicity. Understanding these genetic differences, particularly in targets like the ATP-sensitive potassium channel, is crucial for personalized medicine and effective treatment strategies.
Area of Science:
- Pharmacogenomics
- Molecular Pharmacology
- Genetics
Background:
- Inheritance significantly impacts drug response and toxicity.
- Genetic variations influence inter-individual pharmacokinetics and pharmacodynamics.
- The ATP-sensitive potassium (K(ATP)) channel is a key drug target involved in cellular energy homeostasis.
Purpose of the Study:
- To highlight the role of genetic variability in drug response.
- To emphasize the importance of K(ATP) channel genetics in human disease treatment.
- To underscore the impact of genetic factors on pharmacokinetics and pharmacodynamics.
Main Methods:
- Review of advances in molecular pharmacology.
- Analysis of modern genomics data.
- Case study focusing on the K(ATP) channel.
Main Results:
- Genetic variations are central to understanding differences in drug response.
- K(ATP) channel genetic variability affects membrane excitability regulation.
- Inter-individual differences in drug handling (pharmacokinetics/pharmacodynamics) are genetically determined.
Conclusions:
- Genetic variability in drug targets like the K(ATP) channel is increasingly recognized.
- Understanding genetic influences is vital for optimizing therapeutic decision-making.
- Personalized medicine approaches are essential for managing drug response and toxicity.
More Related Videos
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...